A pilot study of the tolerability of two BCG maintenance regimens in the treatment of high risk superficial bladder cancer

In a single centre UK group of patients, tolerance to maintenance BCG was higher than previously reported by SWOG 8507 and a single dose maintenance regimen was better tolerated than the triplet dose. This review of a non-randomised series of two BCG maintenance regimens is too small to alter current guidelines, but does suggest the need for a much larger multi-centre UK study comparing triplet maintenance with less intense regimens.